Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a biomarker, one researcher said.

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.

INR:9057. marathonbet et Bristol-Myers Squibb's deucravacitinib significantly improves signs and symptoms of psoriatic arthritis Opdivo + Cabometyx combination for ...

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a ...

The distinct radiographic features of psoriatic arthritis (PsA) help confirm it as a distinct entity from rheumatoid arthritis and highlight some unique non-synovial based disease imaging features.

30 Clearly, diagnosis and classification on symptoms alone are insufficient and some form of objective imaging ... good accuracy even without such key variables as psoriasis or rheumatoid factor. The ...

Rheumatoid arthritis (RA) is a form of arthritis and an autoimmune disease. An RA flare, also known as an exacerbation, is when a person experiences transient worsening of their RA symptoms—such as ...